SZN-8141 — IND submission
Q3 2026
Planned IND submission for SZN-8141 in diabetic macular edema by the end of the third quarter of 2026Source filing
SRZN biotech catalysts & pipeline
SURROZEN INC · Data as of 2026-09-08
Upcoming catalysts
SZN-8141 — Initial data
H2 2027
Expect to initiate SZN-8141 Phase 1b/2a study, DUET, by year-end 2026 with initial data anticipated in the second half of 2027Source filing